Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Pfizer has taken a beating in recent years, and its market cap is now around $140 billion. But with the company still ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer is acquiring a pharma company that has multiple GLP-1 drugs in development. The deal may cost the company up to $7.3 billion, which is a move Pfizer can afford to make given its strong ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer enters the new year as a company in transition, but one with a heavily fortified bottom line. Management has set a revenue floor of approximately $61 billion for 2026. This is a realistic, ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

Pfizer (NYSE: PFE)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap ...